Specifically, the association between the most established antiphospholipid antibodies (aPL) – namely lupus anticoagulant (LA), anticardiolipin (aCL), and anti-beta2-glycoprotein I antibodies (aβ2GPI) – and early-onset CIS has been poorly studied. The gene discussed is ACLY; the disease is in situ carcinoma.